Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Portfolio Pulse from
Plus Therapeutics has announced that the FDA has conditionally accepted the proprietary name REYOBIQ™ for its lead drug candidate, which is under investigation for treating CNS cancers. The name will be reviewed once the marketing application is submitted.
March 20, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' lead drug candidate, REYOBIQ™, has received conditional acceptance of its proprietary name from the FDA. This is a positive step in the regulatory process for the drug, which targets CNS cancers.
The FDA's conditional acceptance of the proprietary name REYOBIQ™ is a positive development for Plus Therapeutics as it indicates progress in the regulatory pathway for their lead drug candidate. This could boost investor confidence and potentially impact the stock price positively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100